Oligodendrocyte Apoptosis and Primary Demyelination Induced by Local TNF/p55TNF Receptor Signaling in the Central Nervous System of Transgenic Mice

Models for Multiple Sclerosis with Primary Oligodendrogliopathy

Katerina Akassoglou*, Jan Bauer, † George Kassiotis*, Manolis Pasparakis*, Hans Lassmann, † George Kollias,* and Lesley Probert*

From the Department of Molecular Genetics,* Hellenic Pasteur Institute, Athens, Greece; and the Department of Experimental Neuropathology, † Institute of Neurology, University of Vienna, Vienna, Austria

The scientific dogma that multiple sclerosis (MS) is a disease caused by a single pathogenic mechanism has been challenged recently by the heterogeneity observed in MS lesions and the realization that not all patterns of demyelination can be modeled by autoimmune-triggered mechanisms. To evaluate the contribution of local tumor necrosis factor (TNF) ligand/receptor signaling pathways to MS immunopathogenesis we have analyzed disease pathology in central nervous system-expressing TNF transgenic mice, with or without p55 or p75TNF receptors, using combined in situ terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling and cell identification techniques. We demonstrate that local production of TNF by central nervous system glia potently and selectively induces oligodendrocyte apoptosis and myelin vacuolation in the context of an intact blood-brain barrier and absence of immune cell infiltration into the central nervous system parenchyma. Interestingly, primary demyelination then develops in a classical manner in the presence of large numbers of recruited phagocytic macrophages, possibly the result of concomitant pro-inflammatory effects of TNF in the central nervous system, and lesions progress into acute or chronic MS-type plaques with axonal damage, focal blood-brain barrier disruption, and considerable oligodendrocyte loss. Both the cytotoxic and inflammatory effects of TNF were abrogated in mice genetically deficient for p55TNF receptor-signaling pathways in TNF-mediated pathology. These results demonstrate that aberrant local TNF/p55TNF receptor signaling in the central nervous system can have a potentially major role in the aetiopathogenesis of MS demyelination, particularly in MS subtypes in which oligodendrocyte death is a primary pathological feature, and provide new models for studying the basic mechanisms underlying oligodendrocyte and myelin loss. (Am J Pathol 1998, 153:801–813)

Primary demyelination is a hallmark of multiple sclerosis (MS) and a prominent pathological feature of several other inflammatory diseases of the central nervous system (CNS) that is considered to contribute significantly to functional neurological deficits. It is a complex immune-mediated process that involves the active destruction and phagocytosis of myelin by activated microglia/macrophages and can be accompanied by death of the myelin-forming oligodendrocytes by apoptotic or necrotic processes. The study of animal models such as experimental autoimmune encephalomyelitis (EAE) and Theiler’s virus-induced encephalomyelitis has shown that myelin damage can be triggered by myelin- and non-myelin-specific T cells through release of cytokines and recruitment of macrophages or through the binding of antibodies such as those specific for myelin oligodendrocyte glycoprotein (MOG) to the myelin sheath and targeting of complement and antibody-dependent cell cytotoxicity (ADCC) effector mechanisms. However,
these mechanisms alone are not sufficient to account for the heterogeneous patterns of myelin destruction observed in MS, particularly in a high percentage of patients where oligodendrocyte death is a primary pathological feature.

Considerable evidence has implicated members of the tumor necrosis factor (TNF) ligand/receptor superfamily, particularly TNF and Fas/Fas ligand (FasL), in the pathogenesis of MS. TNF and its receptors (TNFRs) are up-regulated in active MS lesions and levels of TNF in the cerebrospinal fluid of MS patients correlate with disease severity. The described effects of TNF on cultured CNS cells such as astrocyte proliferation, microglial proliferation and reactivity, and endothelial cell activation are consistent with an inflammatory role in the CNS and the induction of immune reactivity. Most relevant to a role in demyelination is increasing evidence that the TNF ligand/receptor system is involved in triggering oligodendrocyte death. Both the p55TNFR and the p75TNFR are selectively expressed on oligodendrocytes located at the edge of active MS lesions and several studies have shown that TNF can kill cultured oligodendrocytes. However, although a large body of information supports a potentially major role for TNF during MS immunopathogenesis and TNF blockade can prevent the development of EAE, recent studies showing that both CNS inflammation and demyelination develop when EAE is induced in TNF- or TNF/lymphoxygen α-deficient mice have called into question the pathogenic potential of TNF along autoimmune-triggered pathways of inflammation and demyelination.

To determine whether local TNF/TNF receptor signaling can play a role in MS aetiopathogenesis, particularly in those subtypes of MS in which demyelinating events precede inflammation and are suggestive of a non-autoantigen-induced mechanism, we have analyzed disease pathology in CNS-expressing TNF transgenic mice and their backcrosses into p55TNFR-deficient backgrounds. We show that local production of TNF by CNS glial cells can selectively induce through the p55TNFR oligodendrocyte apoptosis, primary inflammatory demyelination, and the generation of MS-type plaques which have oligodendrogliopathy as a primary pathological feature.

Materials and Methods

Transgenic and Knockout Mice

TNF transgenic lines Tg6074 and TgK21 express murine TNF-globin and glial fibrillary acid protein (GFAP)-human transmembrane TNF-globin transgenes, respectively, specifically in their CNS. Mice deficient in the p55TNFR (p55/−/−), p75TNFR (p75/−/−) or TNF (TNF/−/−) were generated by homologous recombination in embryonic stem cells and have been described elsewhere. Animal maintenance and appropriate crosses between these strains were performed under specific pathogen-free conditions in the animal facility of the Hellenic Pasteur Institute.

Histopathological Analyses

Mice were transcardially perfused with ice-cold 4% paraformaldehyde (PFA) in PBS under deep ether anesthesia. The partially dissected brain and whole vertebral column were postfixed by immersion in the same fixative for 3 hours at 4°C and transferred into PBS. Brains and spinal cords were dissected and embedded in paraffin. Sections 3 to 5 μm thick were stained with hematoxylin/eosin, Luxol fast blue/periodic acid-Schiff (LFB/PAS), or Bielschowsky silver stain according to standard procedures.

Immunocytochemistry

Immunohistochemical staining was performed on paraffin sections as described elsewhere. Primary antibodies were as follows: rabbit anti-protelipid protein (PLP) (Se-rotec, Oxford, UK) (1/1000), mouse anti-2’ 3’-cyclic nu-cleotide-3’-phosphodiesterase (CNPase) (Affinity, Notting-ham, UK) (1/900), sheep anti-mouse Ig (Amersham, Little Chalfont, UK) (1/200), rabbit anti-cow GFAP (Dako-patts, Glostrup, Denmark) (1/200), rabbit anti-murine TNF (Genzyme, Cambridge, MA) (1/500), rat anti-mouse F4/80 (Sorotec) (1/10), rat anti-mouse Mac-1 (Boehringer-Mannheim, Mannheim, Germany) (1/100), rat anti-human CD3 (Sorotec) (1/400), rabbit anti-mouse S-100 (Serva, Heidelberg, Germany) (1/100), and anti-microtubule associated protein-2 (MAP-2) (kindly provided by G. Wiche, Institute of Biochemistry and Molecular Cell Biology, Vienna) (1/400). Lectin staining was performed using GSI-B4 (Sigma, Deisenhofen, Germany). For double immunostaining peroxidase substrates 3’3’-diaminobenzidine (DAB) (Sigma) and 3- amino-9-ethylcarbazole (AEC) (Sigma) were combined with alkaline phosphatase substrate nitroblue tetrazolium (NBT)/brom-chlor-indolyl phosphate (BCIP) (Boehringer Mannheim).

Figure 1. An S100/CNPaseexv/MAP-2exv CNS glial precursor cell is the cellular source of murine TNF transgene expression in Tg6074 mice. Immunostaining of serial brain sections for TNF (A), S100 (B), and CNPase (C) revealed that the TNF6074 transgene is expressed by a subpopulation of S100-positive cells. Immunostaining of serial brain sections for TNF (D) and MAP-2 (E) revealed that strongly MAP-2 positive neurons (F, arrows) are negative for TNF (G, arrows), while the TNF-positive cell (G, arrowhead) expressed lower levels of MAP-2 (D, arrowhead) when compared to the surrounding neurons (D, arrows). Immunostaining of serial brain sections for TNF (F) and CNPase (F) revealed that the TNF-positive cell also stained weakly for CNPase. CNPase immunostaining of Tg6074 hippocampus demonstrated the weak reactivity of these highly branched precursor cells (arrowhead) when compared to the strong staining of adult oligodendrocytes (arrows). Double immunofluorescence for CNPase (red) and TNF (green) examined by confocal microscopy demonstrated the co-localization (yellow) of the murine TNF transgene in CNPase positive cells. Magnifications: A, B ×792; C-F ×990; G ×355; H ×1608.
with secondary antibodies (rhodamine-conjugated goat anti-mouse (Jackson ImmunoResearch Laboratories, West Grove, PA) and biotinylated sheep anti-rabbit (Amersham)) for 2 hours at room temperature. In a third step, sections were incubated with avidin-conjugated Cy2 (Amersham) for 1 hour at room temperature. After rinsing with PBS, sections were embedded in PBS/glycerol (1:9) with 3% DABCO (Sigma) and placed in a coverslip. Fluorescent preparations were examined using a Carl Zeiss laser scan microscope equipped with an argon laser (488 and 514 nm excitation) and two HeNe lasers (543 and 633 nm excitation) (Carl Zeiss, Jena, Germany). The rhodamine fluorescence (CP2ase) was excited with the 543-nm laser. The emitted light was detected on photomultiplier 2 with a 557–640 bandpass filter. Cy2 (TFN) was excited with the 488-nm laser and was detected on photomultiplier 3 using a 515–565 bandpass filter. Scanning with the 543- and 488-nm lasers was performed sequentially. After this, sections made with 543- and 488-nm lasers lying in the same Z plane were merged to produce a single picture. Overlaid pictures were printed with a Sony digital color printer (Cy2 signal green, rhodamine red, co-localization yellow).

In Situ Detection of Nuclear DNA Fragmentation

Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling (TUNEL) was performed on paraffin sections as described previously. Sections were double-labeled with antibodies to CPNase or GFAP using AEC or DAB for color development. Sections were counterstained with hematoxylin.

In Situ Hybridization of PLP mRNA

Detection of PLP mRNA was performed on brain and spinal cord paraffin sections. Nonisotopic in situ hybridization was performed as described. Briefly, 5-μm paraffin sections were dewaxed, pretreated with 10 μg of proteinase K (Sigma) in Tris-buffered solution, pH 7.2, and incubated with digoxigenin-labeled probes specific for PLP. Sections were incubated for 1 hour with alkaline phosphatase-labeled anti-digoxigenin antibody (Boehringer-Mannheim). Substrate was visualized using NBT/BCIP (Boehringer-Mannheim). All sections were double-stained with anti-PLP antibodies as described above with triple APAAP using Fast Red as substrate. Sections were counterstained with hematoxylin.

Electron Microscopic Analyses

Animals were intracardially perfused under deep ether anesthesia with ice-cold 2% PFA, 0.5% glutaraldehyde in 0.1 mol/L phosphate buffer, pH 7.2, for 1 minute followed by ice-cold 3% glutaraldehyde in 0.1 mol/L phosphate buffer for 5 minutes. Brains and spinal columns were removed, immersion-fixed for 24 hours in phosphate-buffered 3% glutaraldehyde, postfixed in 2% osmium tetroxide solution, and subsequently embedded in epoxy resin. Ultrathin sections were cut and counterstained with uranyl acetate and lead citrate.

Results

Cellular Source of Murine TNF and Human Transmembrane TNF Transgene Expression in Tg6074 and TgK21 Mice

Transgenic mice which show CNS-specific expression of a murine TNF transgene (the Tg6074 line) or astrocyte-targeted expression of an uncleavable transmembrane human TNF mutant (the TgK21 line) have been reported previously. TgK21 mice express human transmembrane TNF under the control of the GFAP promoter region, and immunocytochemistry on serial spinal cord sections with antibodies to human TNF and GFAP showed that the TNF transgene is expressed by GFAP-positive astrocytes. To identify the precise cellular source of murine TNF transgene expression in the CNS of Tg6074 mice, we have used immunocytochemical techniques to localize murine TNF immunoreactivity in the CNS. Tissues were taken from Tg6074TNF−/− double transgenic mice to exclude simultaneous expression from the endogenous TNF gene. Transgene-positive cells had a highly ramified appearance and were numerous throughout the brain in both white and gray matter. Double immunostaining for murine TNF and markers for mature CNS cell types showed that the TNF transgene is not expressed in either GFAP-positive astrocytes or F4/80-, Mac-1-, or GSI-B4 lectin-positive microglia/macrophages (not shown). Single immunostaining of serial 0.5- to 1-μm paraffin sections for TNF and S100 (marker for astrocytes and immature glia) showed that TNF immunoreactive cells show low immunoreactivity for all of these markers when compared to mature cell lineages, indicating that they are probably CNS glial progenitor cells. Examination
Figure 3. Primary demyelination develops in Tg6074 transgenic mice. At 4 weeks of age, semithin sections revealed myelin vacuolation (A, arrows). Electron microscopy of the same area as Figure 3A reveals large vacuoles in the myelin sheath (B). At 9 weeks of age, semithin sections revealed active primary demyelination characterized by high numbers of phagocytic macrophages (C, arrowheads), and the presence of naked axons (C, open arrows). (D) Electron microscopy of the same area as Figure 3C shows a cluster of demyelinated axons in the close vicinity of phagocytic macrophages (M). In the middle a single myelinated axon can still be seen. Magnifications: A, ×740; B, ×4133; C, ×925; D, ×6125.
of double-stained sections for TNF and CNPase by confocal microscopy confirmed that the TNF transgene is expressed by CNPase-positive cells (Figure 1H).

CNS Expression of Murine TNF in Tg6074 Transgenic Mice Triggers Oligodendrocyte Apoptosis, Primary Demyelination, and Formation of Chronic MS-Type Plaques

To determine the effect of expression of a murine TNF transgene by resident cells of the CNS on oligodendrocytes and myelin in vivo, we carried out a detailed histopathological and ultrastructural analysis of disease in Tg6074 transgenic mice (Figures 2 and 3, Tables 1 and 2).

The first histopathological changes were observed from 1 week of age and involved single-scattered oligodendrocytes which stained positively for TUNEL and showed nuclear changes characteristic of apoptosis in the corpus callosum (Figure 2C), the initial site of transgene expression, together with widespread microglial activation. Oligodendrocyte apoptosis developed in the absence of immune infiltration and blood-brain barrier (BBB) damage in the CNS parenchyma (not shown), although minimal BBB damage and immune infiltration could be observed at the meninges.

By 4 weeks of age, early demyelinating events consisting of myelin swelling and the formation of vacuoles with single fiber degeneration were observed (Tables 1 and 2). This was localized by luxol fast blue staining or PLP in situ hybridization and immunocytochemistry for PLP protein in the cerebellar white matter, the capsula interna (Figure 2, A and B), and, to a minor degree, the optic tracts. Examination of semithin (Figure 3A) and thin (Figure 3B) sections by electron microscopy showed myelin swelling within the periaxonal space of the myelin sheath. Axons within the demyelinating area appeared intact (Figure 3B), showing that TNF-mediated CNS damage is selective for oligodendrocytes and myelin. Although there was pronounced inflammation at the brain meninges at this stage, immune cell infiltration in the brain parenchyma and BBB leakage were minor. The myelin vacuolation observed in transgenic mice closely resembled that seen in chronic MS lesions and other demyelinating diseases such as HIV vacular myelopathy, which is associated with massive vacuolation of myelin, axonal preservation, and in part with infiltration of the periaxonal space by macrophages/microglia.

In later lesions (8 to 10 weeks of age), confluent symmetrical plaques of primary demyelination had developed in all animals tested (Tables 1 and 2). Plaques were characterized by loss of both myelin and oligodendrocytes as shown by double PLP in situ hybridization and PLP immunocytochemistry (Figure 2G), and oligodendrocyte apoptosis (Figure 2D) but remyelinating events were not observed. Ultrastructural analysis showed the presence of numerous demyelinated axons within the lesions (Figure 3D). In the plaque there were also abundant activated microglia/macrophages (Figures 2E, 3C, and 3D) and at the plaque edge several of these cells contained myelin degradation products (Figure 2F) demonstrating active myelin degradation. Moderate axonal damage was evident within the plaques (Figure 2H). Such lesions are accompanied by BBB leakage, some perivascular lymphocyte infiltration (Figure 2I), and astroglial scarring. All histopathological changes described were restricted to brain samples where the transgene is abundantly expressed. Such demyelinating plaques remarkably resemble those of chronic MS lesions.

Astrocytic Expression of Transmembrane Human TNF Triggers Oligodendrocyte Apoptosis, Primary Demyelination with Axonal Loss, and the Development of Acute MS-Type Lesions

To investigate whether a human transmembrane TNF protein expressed by astrocytes could also trigger oligodendrocyte and myelin damage in vivo and thereby assess the importance of p55TNFR signaling via a contact-dependent manner, we also analyzed CNS tissues from TgK21 transgenic mice (Figure 4 and Table 3).

Histopathological changes were detected from the first week of age in all mice tested as a progressive accumulation of inflammatory cells with associated BBB damage at the meninges of the spinal cord and widespread astrocytic gliosis (not shown). In situ TUNEL counterstained for CNPase revealed the selective apoptosis of oligoden-
Table 2. Myelin Pathology in the Cerebellum of Tg6074 Transgenic Mice

<table>
<thead>
<tr>
<th>Age (wk)</th>
<th>Mice (n)</th>
<th>Normal (%)</th>
<th>Vacuolation (%)</th>
<th>Demyelination (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4–6</td>
<td>4</td>
<td>60 ± 5.2</td>
<td>40 ± 6.2</td>
<td>0</td>
</tr>
<tr>
<td>6–8</td>
<td>6</td>
<td>23 ± 5.1</td>
<td>27 ± 10.2</td>
<td>50 ± 9.9</td>
</tr>
<tr>
<td>10</td>
<td>4</td>
<td>18 ± 3.3</td>
<td>30 ± 17.0</td>
<td>53 ± 19.0</td>
</tr>
</tbody>
</table>

The total area of cerebellar white matter (average, 0.5 mm²) and the relative proportions (% with SEM) of demyelinated (confluent) and vacuolated areas were determined using an ocular morphometric grid.

dendrocytes from the second week of age (not shown). By the fourth week of age, demyelinating lesions covering 30% of the original myelin mass (Figure 4A) had developed in the spinal cord at sites of extreme inflammation (Figure 4G) and extensive BBB breakdown (Figure 4F). Myelin loss was accompanied by axonal damage (Figure 4B) and astrocyte loss (Figure 4C). The presence of numerous phagocytic macrophages containing PLP positive myelin degradation products in the affected areas (Figure 4, D and E) showed that myelin was being phagocytosed by these cells. As in chronic lesions mentioned above, in situ hybridization for PLP mRNA showed that PLP-expressing oligodendrocytes were progressively depleted from demyelinating lesions (not shown). Combined TUNEL/CNPase immunocytochemistry showed that this loss could be accounted for at least in part by oligodendrocyte apoptosis (Figure 4, H–J). Interestingly, TNF triggered demyelination selectively in CNS myelin, leaving myelin of the peripheral nervous system intact (Figure 4E). The histopathological and ultrastructural characteristics of spinal cord lesions in TgK21 mice are consistent with those observed in typical acute MS, where destructive lesions include loss of myelin, oligodendrocytes, axons, and astrocytes.

The p55TNFR Is Necessary for the Development of TNF-Triggered CNS Inflammation and Primary Demyelination in Transgenic Mice

The present findings that both murine and human TNF can trigger the development of CNS inflammation, oligodendrocyte apoptosis, and demyelination in transgenic mice indicate that the p55TNFR plays a dominant role in the initiation of this phenotype, as human TNF is unable to signal through the murine p75TNFR. To investigate further the specificity of TNF signaling in TNF-triggered CNS pathology, we generated Tg6074 and TgK21 transgenic mice which were deficient in the p55TNFR and Tg6074 mice which were deficient for the p75TNFR. All Tg6074p55−/− and TgK21p55−/− mice generated remained entirely free of clinical symptoms for the study period of 8 months, while Tg6074p55+/+ and TgK21p55++ littermates developed disease as expected by 4 and 3 weeks of age, respectively. Histopathological analysis of CNS tissues from Tg6074p55−/− (n = 4) and TgK21p55−/− (n = 5) mice aged up to 6 months found no evidence of inflammation or demyelination (Figure 5A), showing that the presence of the p55TNFR is necessary for TNF to trigger these effects. Interestingly, TgK21p55+/− mice developed much delayed neurological symptoms by the sixth month of age. At the histological level the CNS from such mice (n = 2) showed symmetrical, focal demyelinated plaques at the capsule interna and in the spinal cord (not shown). In contrast, Tg6074p55+/− mice remained symptom-free during a study period of 12 months, and such mice (n = 2) showed no sign of pathology at the histological level. These results show that the levels of expression of the p55TNFR play a critical role in determining the pattern and extent of TNF-triggered CNS inflammation and primary demyelination in vivo. In contrast to Tg6074p55−/− mice, CNS pathology developed in Tg6074p75−/− (n = 2) mice with myelin vacuolation, inflammation and oligodendrocyte apoptosis as in Tg6074p75+/+ controls (Figure 5, B–E), showing that when TNF is overexpressed it can trigger both inflammation and demyelination through the p55TNFR, even in the absence of the p75TNFR.

Discussion

Through the application of modern immunopathology techniques such as those which allow the precise histopathological identification of cell death and cell proliferation processes to the study of MS, it has become clear that MS lesions and patterns of demyelination are heterogeneous among patients and may therefore be mediated by different pathological mechanisms. In some pa-
tients myelin damage proceeds with preservation of oligodendrocytes, whereas in others oligodendrocytes are the primary target of the destructive process. To explain the relative selectivity of degeneration of myelin in MS, emphasis has been given to autoimmune-mediated mechanisms of demyelination. The study of EAE has provided important information concerning mechanisms of T cell-mediated and antibody-mediated demyelination where macrophages are important effector cells. However, oligodendrocyte death does not seem to be a feature of EAE and remyelination capacity is retained. It is clear that certain subtypes of MS, particularly those showing primary oligodendrogliopathy and absence of remyelinating events, cannot be accounted for by such antigen-triggered processes alone. TNF is a potent inflammatory mediator which is involved at multiple levels of immune regulation and has also been strongly implicated in the pathogenesis of neuroinflammatory and demyelinating diseases. In this study we demonstrate that TNF produced by resident CNS glia in two transgenic mouse lines can selectively induce oligodendrocyte apoptosis and primary demyelination in vivo as primary pathogenic effects. Myelin vacuolation observed in early transgenic lesions closely resembled that observed in MS and HIV-induced vacuolar myelopathy and depending on the context of TNF transgene expression in the CNS the demyelinating process progressed to the development of classical chronic or destructive acute MS-type lesions.

The molecular and cellular mechanisms by which TNF induces CNS inflammation and demyelination in transgenic mice appear to be very specific. The p55TNFR is known to mediate cell death responses (apoptosis) and proliferative effects by differential signaling through intracellular pathways. Our observation that oligodendrocyte apoptosis is one of the first pathological effects of TNF transgene expression in the CNS suggests that TNF may exert a direct cytotoxic effect on oligodendrocytes. This is substantiated by evidence showing that oligodendrocytes can express TNFRs both in vitro and in MS lesions and by ample evidence that TNF can trigger oligodendrocyte death in vitro. Furthermore, the recent finding that inhibitors of ICE/CED-3 proteases prevent TNF-mediated oligodendrocyte apoptosis show that at least in vitro TNF can trigger intracellular death-signaling pathways in these cells. The observed concurrent inflammatory effects of TNF in the CNS of transgenic mice, including astrocytosis, microgliosis, and endothelial cell activation are likely to contribute significantly to progression of the demyelinating process and plaque formation through additional inflammatory mechanisms of myelin and axonal damage. The development of conditional mutant mice in which the p55TNFR can be activated or inactivated in specific CNS cell lineages will allow the individual contributions of different TNF-mediated effects to CNS inflammation and demyelination to be evaluated. Further to an essential role for the p55TNFR in the initiation of TNF-mediated inflammation and demyelination, our studies in transgenic mice have demonstrated that the cellular source of TNF expression within the CNS also plays a critical role in determining whether inflammation and demyelination will develop. Our finding that transmembrane human TNF can trigger demyelination when produced by astrocytes but not neurons and the observation by others that transmembrane TNF is more effective than soluble TNF in killing oligodendrocytes in vitro strongly suggest that transmembrane TNF-mediated demyelination depends on appropriate cellular contacts between TNF-producing cells and oligodendrocytes or intermediate cells such as microglia/macrophages, and implicate transmembrane TNF as an important effector of oligodendrocyte death in vivo.

Although primary demyelination is the major hallmark of MS, axonal loss correlates with inflammatory activity and is observed in lesions as they age. Similarly, in TNF transgenic mice axonal damage is not observed as a primary pathogenic effect of TNF expression suggesting that neurons, in contrast to oligodendrocytes, may not be direct targets of TNF cytotoxicity in vivo but are damaged following immune infiltration at sites of oligodendrocyte/myelin damage. This conclusion is consistent with several lines of evidence which show that TNF can be neuroprotective probably through the induction of NF-κB and NF-κB-regulated genes in neurons. Our observation that the context of TNF expression within the CNS determines whether the resulting lesion will be chronic or acute may therefore relate to the differential capacity of TNF to trigger parenchymal inflammation and BBB leakage from different cell sources. TNF induces the development of acute demyelinating lesions when expressed by astrocytes in TgK21 mice. Astrocytes form intimate associations with the BBB through their foot pro-

### Table 3. Time Course and Extent of Pathology in TgK21 Mouse Spinal Cord

<table>
<thead>
<tr>
<th>Age</th>
<th>Mice (n)</th>
<th>Inflammation</th>
<th>Oligodendrocyte apoptosis</th>
<th>Myelin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Meninges</td>
<td>Parenchyma</td>
<td>Normal (%)</td>
</tr>
<tr>
<td>1</td>
<td>2</td>
<td>+</td>
<td>−</td>
<td>100</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>+</td>
<td>−</td>
<td>100</td>
</tr>
<tr>
<td>3</td>
<td>3</td>
<td>+/+/−</td>
<td>+</td>
<td>100</td>
</tr>
<tr>
<td>4</td>
<td>3</td>
<td>+</td>
<td>+</td>
<td>67 ± 8</td>
</tr>
</tbody>
</table>


Directions: +, present; −, not present. The total area of spinal cord white matter (average, 0.5 mm²) and the relative proportions (% with SEM) of demyelinated (confluent) areas were determined using an ocular morphometric grid.
cesses and induce BBB properties in CNS endothelial cells in vitro and astrocyte-specific expression of TNF seems to be crucial for endothelial cell activation and BBB damage in transgenic mice (Akassoglou, Bauer, Lassmann, Kollias, and Probert, unpublished observations), suggesting a vigorous inflammatory component characteristic of acute demyelinating lesions with axonal loss. Taken together, these results indicate that whereas oligodendrocyte apoptosis is primary and TNF-dependent, axonal damage is secondary to BBB damage and immune cell infiltration of the CNS and points to the interesting possibility that axonal damage in MS, which is largely responsible for permanent disability, may be limited by treatments that restrict leukocyte trafficking at the BBB irrespective of disease etiology.

Our results demonstrate that TNF is a potent and selective effector of oligodendrocyte death and primary demyelination in vivo and implicate TNF/p55TNFR signaling as a potentially important mechanism of non-antigen-driven demyelination in MS. In addition, the characterization of the p55TNFR as the dominant receptor in mediating TNF-induced oligodendrocyte cytotoxicity and inflammation in the CNS identifies p55TNF signaling pathways as potentially important targets for cell-specific interventions. The finding that TNF-induced lesions in mice bear remarkable histopathological resemblance to MS lesions, particularly those characterized by primary oligodendrogiopathy, establish TNF transgenic mice as new animal models for MS.

**Acknowledgments**

We thank Dr. Horst Bluethmann for providing the p55TNFR knockout mice, Dr. Mark Moore for providing the p75TNFR knockout mice and Dr. Roly Foulkes (Celltech, Berkshire, UK) for the TN3 neutralizing anti-murine TNF antibodies used for maintenance of the Tg6074 line. We also thank Helene Breitschopf, Angela Kury, Elisabeth Gurnhofer, Anna Kefalaki, Marianne Leisser, and Spiridoula Papandreou for expert technical assistance.
References

30. Raine CS: Demyelinating diseases. Textbook of Neuropathology. Ed-